Sun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...

The Indian government is refining biosimilar drug regulations, aligning with global standards to ensure stringent quality in research and m...

The Delhi High Court has temporarily barred Zydus Lifesciences from selling its breast cancer drug Sigrima, a biosimilar of Roche's Perjeta...

Dr Reddy's Laboratories (DRL) and Intas Pharmaceuticals, both Indian companies, are reportedly in the race to acquire the biosimilar produc...

Biological drugs are harvested from living organisms or certain components of living organisms. These drugs are very specific and highly ef...

Strong annual results for 2018-19 including improvement in net profit, growth momentum in its biosimilars business and recent price correct...

Biosimilar drugs are the follow on versions of biologic drugs which are composed of sugars, proteins, nucleic acids or complex combinations...

"Our clinical data package has been approved by ODAC recently, and the GMP part of the regulatory process has already seen us-- provide a s...

The court’s latest move, which allows the companies to use Roche’s product data in their package inserts, is expected to allow Biocon and M...

Legal experts said that the court is still in the process of hearing arguments from both sides to ascertain whether Roche could have approa...

Gennova's drug can't be approved as a biosimilar of tenecteplase as the original drug isn't prescribed for strokes, argued P Chidambaram, c...

The ministry expects the final guidelines to uphold the safety and efficacy of biosimilar drugs hitting the Indian market through stringent...

Roche, which invented the drug and markets it under the blockbuster brand ‘Avastin’, has argued that Hetero’s drug is not a biosimilar to b...

The judge asked the company to submit a compilation of judgments highlighting the protection given to drug innovators to support its call.

The order, which raised questions on the processes followed by the Indian drug controller in approving such drugs, could also affect the av...

Bangalore-based Biocon and US generic drugmaker Mylan have challenged Delhi High Court’s interim order which barred them from using Roche’s...

Joining Indian pharma majors who are targeting the $65-billion global biotech drug market.